Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation

Background There is significant interest in NO pathway modulators, specifically type 5 phosphodiesterase inhibitors (PDE5is), to treat patients with a Fontan circulation. Trials, however, have had mixed results. The relationship between the NO pathway and clinical status in patients with Fontan circ...

Full description

Bibliographic Details

Published in:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Main Authors:	Ari Cedars, Cedric Manlhiot, Bhargava Kumar Chinni, Alexander R. Opotowsky, Kristian Becker, Anne Le, Pratik Khare, Jong Love Ko, Allen Everett, Shelby Kutty, Mark W. Russell, R. Mark Payne, Andrew M. Atz, Brian W. McCrindle, Rahul H. Rathod, Matthew Lewis, David Goldberg, Kevin Hill, Michelle Ploutz, Jon Detterich, Kurt Schumacher, Robert Whitehill, Daniel J. Penny, Mark Cartoski, Rachel Sullivan, Matthew Files, Ruchira Garg, Jonathan Wagner, Roni Jacobsen, Todd Nowlen, Scott Fletcher, Jennifer Conway, Gi Boem Kim, Fred Wu, Victor Zak
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Subjects:	Fontan metabolomics nitric oxide type 5 phosophodiesterase inhibitor
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.124.038061